Orphazyme CEO excited for milestone: We are preparing for all scenarios
BY KEVIN GRØNNEMANN
In Q3, when Orphazyme receives the first phase III results of the main assetarimoclomol, the company will reach a major milestone. This is according to CEO Anders Hinsby, who has confidence in the study but is preparing for all possible scenarios.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.